Matches in Nanopublications for { ?s ?p "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP7366.RAIeyBjramGDHt3_ic1ccCv7yxWBkUfEWSIwIf8cgi54s130_provenance.
- NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799692.RAqtRMKIKiGXj4krd2Sh_Sc80Aa-fbdKhMJM7rM91KePk130_provenance.
- assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP348009.RATsH-caarwkVJtE3sDtauEbRMjLh_Xsy2p53kGL847yY130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP348009.RATsH-caarwkVJtE3sDtauEbRMjLh_Xsy2p53kGL847yY130_provenance.
- assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922821.RAdP08yme3EEEZImiX5pytBtnoXcyNhwA3KxqRnwXcufo130_provenance.
- NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_assertion description "[The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP922822.RAKeIgeTyEu7rGjyphHXbj14ZXWEdtH0jlS-1H7PtzTU0130_provenance.